Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone

Aimaz Afrough, MD, Amy Sidorski, CRNP, Roberto Salvatori, MD, Ivan Borrello, MD

Blood (2016) 128 (22): 5640.

https://doi.org/10.1182/blood.V128.22.5640.5640

Published: 2016

Journal Articles

Marrow Infiltrating Lymphocytes and Vaccines in Myeloma

Ivan Borrello, MD

Blood (2016) 128 (22): SCI-35.

https://doi.org/10.1182/blood.V128.22.SCI-35.SCI-35

Published: 2016

Journal Articles

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Kimberly A Noonan, PhD MPH, Lakshmi Rudraraju, MS, Valentina Hoyos, MD, Eric Lutz, PhD, Ivan Borrello, MD

Blood (2016) 128 (22): 4552.

https://doi.org/10.1182/blood.V128.22.4552.4552

Published: 2016

Journal Articles

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

Laura K Schoch, MS, CRNP, Ivan Borrello, MD, Ephraim J. Fuchs, MD, Javier Bolanos-Meade, MD, Jeffrey Sean Huo, MD PhD, Ivana Gojo, MD, Nina Wagner-Johnston, MD, Gabrielle T Prince, MD, Shannon R. McCurdy, MD, B. Douglas Smith, MD, Amy E. DeZern, MD MHS, Margaret M. Showel, MD, David Loeb, MD PhD, Aziza T. Shad, MD, Richard J Jones, MD, Richard F. Ambinder, MD PhD, Douglas Gladstone, MD

Blood (2016) 128 (22): 4571.

https://doi.org/10.1182/blood.V128.22.4571.4571

Published: 2016

Journal Articles

The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies

Valentina Hoyos, Ivan Borrello

Blood (2016) 128 (13): 1679–1687.

https://doi.org/10.1182/blood-2016-05-636357

Published: 2016

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

Kimberly Noonan, PhD MPH, Carol Ann Huff, Amy Sidorski, NP, Anna Ferguson, RN, Lakshmi Rudraraju, MS, Andrea Casildo, BS, Ivan Borrello, MD

Blood (2014) 124 (21): 2137.

https://doi.org/10.1182/blood.V124.21.2137.2137

Published: 2014

Journal Articles

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Philippe Armand, MD PhD, Stephen M. Ansell, MD PhD, Alexander M. Lesokhin, MD, Ahmad Halwani, MD, Michael M. Millenson, MD, Stephen J. Schuster, MD, John Timmerman, MD, Ivan Borrello, MD, Martin Gutierrez, MD, Emma C. Scott, MD, Deepika Cattry, MSc, CCRP, Bjoern Chapuy, MD PhD, Azra H. Ligon, PhD, Scott J. Rodig, MD PhD, Lili Zhu, MSc, Joseph F. Grosso, PhD, Su Young Kim, MD PhD, Margaret A. Shipp, MD

Blood (2014) 124 (21): 289.

https://doi.org/10.1182/blood.V124.21.289.289

Published: 2014

Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Blood (2014) 124 (21): 291.

https://doi.org/10.1182/blood.V124.21.291.291

Published: 2014

Journal Articles

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells

Toshihiko Tanno, Yiting Lim, Qiuju Wang, Marta Chesi, P. Leif Bergsagel, Geoff Matthews, Ricky W. Johnstone, Nilanjan Ghosh, Ivan Borrello, Carol Ann Huff, William Matsui

Blood (2014) 123 (5): 725–733.

https://doi.org/10.1182/blood-2013-08-524025

Published: 2014

Includes: Supplemental data

Journal Articles

A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma

Kimberly Noonan, Luigi Marchionni, Judy Anderson, Drew Pardoll, G. David Roodman, Ivan Borrello

Blood (2010) 116 (18): 3554–3563.

https://doi.org/10.1182/blood-2010-05-283895

Published: 2010

Journal Articles

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Leo Luznik, Javier Bolaños-Meade, Marianna Zahurak, Allen R. Chen, B. Douglas Smith, Robert Brodsky, Carol Ann Huff, Ivan Borrello, William Matsui, Jonathan D. Powell, Yvette Kasamon, Steven N. Goodman, Allan Hess, Hyam I. Levitsky, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs

Blood (2010) 115 (16): 3224–3230.

https://doi.org/10.1182/blood-2009-11-251595

Published: 2010

Journal Articles

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation

Paria Mirmonsef, Gladys Tan, Gang Zhou, Tricia Morino, Kimberly Noonan, Ivan Borrello, Hyam I. Levitsky

Blood (2008) 111 (4): 2112–2121.

https://doi.org/10.1182/blood-2007-06-096586

Published: 2008

Journal Articles

Th-17 Lymphocytes, Not Regulatory T Cells, Mediate Immune Regulation of Bone Marrow Infiltrating Lymphocytes and Induce Osteoclast Activation in Multiple Myeloma.

Kimberly A. Noonan, Judy Anderson, Stephanie Mgebroff, Paolo Serafini, David Roodman, Ivan Borrello

Blood (2007) 110 (11): 811.

https://doi.org/10.1182/blood.V110.11.811.811

Published: 2007

Journal Articles

CD4+CD25+ Marrow Infiltrating Lymphocytes in Myeloma Patients Display an Activated Phenotype and Lack Suppressive Function.

Kimberly A. Noonan, MPH, Stephanie Mgebroff, BS, Paolo Serafini, PhD, Kristen Meckel, BS, Mark Bonyhadi, PhD, Ivan Borrello, MD

Blood (2006) 108 (11): 1741.

https://doi.org/10.1182/blood.V108.11.1741.1741

Published: 2006

Journal Articles

Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity.

Ivan Borrello, MD, Anna Ferguson, RN, Carol Ann Huff, MD, Shirley George, BS, Barbara Biedryzcki, CRNP, David Cornblath, MD, Vinay Chaudhry, MD

Blood (2006) 108 (11): 3528.

https://doi.org/10.1182/blood.V108.11.3528.3528

Published: 2006

Journal Articles

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

David Siegel, MD, PhD, Sundar Jagannath, MD, Amitabha Mazumder, MD, David Vesole, MD, Ivan Borrello, MD, Jens Sydor, PhD, Jim Wright, PhD, Jon Patterson, BS, Emmanuel Normant, PhD, Julian Adams, PhD, Kenneth Anderson, MD, David Grayzel, MD, Paul Richardson, MD

Blood (2006) 108 (11): 3579.

https://doi.org/10.1182/blood.V108.11.3579.3579

Published: 2006

Journal Articles

In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity

Pedro Horna, Alex Cuenca, Fengdong Cheng, Jason Brayer, Hong-Wei Wang, Ivan Borrello, Hyam Levitsky, Eduardo M. Sotomayor

Blood (2006) 107 (7): 2871–2878.

https://doi.org/10.1182/blood-2005-07-3014

Published: 2006

Journal Articles

Autologous Tumor Combined with a GM-CSF-Secreting Cell Line Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma.

Ivan Borrello, Barbara Biedrzycki, Nicole Sheets, Beena George, Frederick Racke, Kathy Loper, Kimberly Noonan, Amy Donnelly, Kristen Hege, Hyam Levitski

Blood (2004) 104 (11): 440.

https://doi.org/10.1182/blood.V104.11.440.440

Published: 2004

NARROW

The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone

Marrow Infiltrating Lymphocytes and Vaccines in Myeloma

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide.

The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells

A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation

Th-17 Lymphocytes, Not Regulatory T Cells, Mediate Immune Regulation of Bone Marrow Infiltrating Lymphocytes and Induce Osteoclast Activation in Multiple Myeloma.

CD4+CD25+ Marrow Infiltrating Lymphocytes in Myeloma Patients Display an Activated Phenotype and Lack Suppressive Function.

Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity.

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity

Autologous Tumor Combined with a GM-CSF-Secreting Cell Line Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only